Spero Therapeutics Management
Management criteria checks 0/4
Key information
Sath Shukla
Chief executive officer
US$2.0m
Total compensation
| CEO salary percentage | 25.9% |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 1.4yrs |
| Board average tenure | 9.9yrs |
Recent management updates
Recent updates
Spero Therapeutics Delivers On Game Plan To Create Shareholder Value
Apr 23Spero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 27%
Mar 12
Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Jan 02Need To Know: Analysts Just Made A Substantial Cut To Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Estimates
May 18Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Fly 26% But Investors Aren't Buying For Growth
Apr 17Industry Analysts Just Upgraded Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Revenue Forecasts By 40%
Apr 13We Think Spero Therapeutics (NASDAQ:SPRO) Can Easily Afford To Drive Business Growth
Apr 05Spero Therapeutics: The GlaxoSmithKline-Deal Changes Everything And Protects Shareholder Value
Oct 03Spero Therapeutics appoints Kamal Hamed MD CMO
Sep 15Spero jumps 64% as FDA clarifies future regulatory path for UTI candidate
Sep 06Spero Therapeutics GAAP EPS of -$0.87, revenue of $1.99M
Aug 10We're A Little Worried About Spero Therapeutics' (NASDAQ:SPRO) Cash Burn Rate
Jul 04We're Hopeful That Spero Therapeutics (NASDAQ:SPRO) Will Use Its Cash Wisely
Mar 17Sizing Up Spero Therapeutics
Oct 15Spero Therapeutics, Inc.'s (NASDAQ:SPRO) CEO Compensation Looks Acceptable To Us And Here's Why
Aug 11Are Institutions Heavily Invested In Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Shares?
Feb 23CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$2m | US$524k | US$23m |
| Sep 30 2023 | n/a | n/a | -US$2m |
| Jun 30 2023 | n/a | n/a | -US$10m |
| Mar 31 2023 | n/a | n/a | -US$27m |
| Dec 31 2022 | US$2m | US$478k | -US$46m |
| Sep 30 2022 | n/a | n/a | -US$102m |
| Jun 30 2022 | n/a | n/a | -US$113m |
| Mar 31 2022 | n/a | n/a | -US$103m |
| Dec 31 2021 | US$2m | US$441k | -US$90m |
CEO
Sath Shukla (50 yo)
less than a year
Tenure
US$2,024,647
Compensation
Mr. Satyavrat Shukla, also known as Sath, C.F.A., has been President, Chief Executive Officer and Director at Spero Therapeutics, Inc. since August 1, 2023. He had been the Chief Financial Officer of Spero...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Chairman of the Board | 10.6yrs | US$2.39m | 0.41% $ 316.6k | |
| President | less than a year | US$2.02m | no data | |
| Chief Operating Officer | 1.2yrs | US$1.44m | 0.12% $ 91.9k | |
| CFO, Chief Business Officer & Treasurer | less than a year | no data | no data | |
| Chief Human Resource Officer | 2.4yrs | no data | no data | |
| Chief Medical Officer | 1.6yrs | no data | 0.23% $ 174.8k |
1.4yrs
Average Tenure
50yo
Average Age
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Chairman of the Board | 10.6yrs | US$2.39m | 0.41% $ 316.6k | |
| President | less than a year | US$2.02m | no data | |
| Independent Director | 6.8yrs | US$82.07k | 0.028% $ 21.6k | |
| Independent Director | 10.3yrs | US$109.55k | 0.058% $ 45.3k | |
| Scientific Advisors | 9.9yrs | no data | no data | |
| Clinical Advisor | 9.9yrs | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Lead Independent Director | 8.6yrs | US$93.19k | 0.028% $ 21.6k | |
| Clinical Advisor | 9.9yrs | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Clinical Advisor | 9.9yrs | no data | no data | |
| Independent Director | 5.1yrs | US$73.20k | 0.028% $ 21.6k |
9.9yrs
Average Tenure
57yo